You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 11,752,198

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,752,198

Title:	GLP-1 compositions and uses thereof
Abstract:	The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
Inventor(s):	Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
Assignee:	Novo Nordisk AS
Application Number:	US17/115,773
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,752,198
Patent Claims:	1. A liquid pharmaceutical composition comprising: semaglutide; wherein said composition does not contain phenol; is for parenteral administration; is an aqueous solution comprising at least 60% (w/w) water; or further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; and wherein the semaglutide is in the range of 0.01 mg/ml-10.0 mg/ml; and wherein the pH of the composition is in between 7.0 and 7.8; wherein the liquid pharmaceutical composition exhibits improved chemical and/or physical stability as compared to a liquid pharmaceutical composition that contains phenol. 2. The liquid pharmaceutical composition according to claim 1, wherein the concentration of semaglutide is selected from 0.5-10 mg/ml or 0.01-5 mg/ml of said composition. 3. The liquid pharmaceutical composition according to claim 1, wherein said composition comprises no added pharmaceutical preservative. 4. The liquid pharmaceutical composition according to claim 1, wherein said parenteral administration is subcutaneous administration. 5. A kit comprising the liquid pharmaceutical composition according to claim 1 and instructions for use. 6. A kit comprising the liquid pharmaceutical composition according to claim 1 and an injection device for administration of said composition to a subject, wherein said injection device is selected from the group consisting of a durable pen and a prefilled pen. 7. A method of treating diabetes comprising administering to a subject in need of such method a therapeutically effective amount of the pharmaceutical composition according to claim 1. 8. A method of treating obesity comprising administering to a subject in need of such method a therapeutically effective amount of the pharmaceutical composition according to claim 1. 9. The liquid pharmaceutical composition according to claim 1, wherein said composition has a pH in the range of 7.0-7.4.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.